Pyoderma gangrenosum - Pyoderma Gangraenosum
Pyoderma Gangraenosum (Pyoderma gangrenosum) rarum est, morbus inflammatorius cutis, in quo dolor pusulorum aut nodulorum, ulceribus paulatim crescens, occurrit. Pyoderma Gangraenosum (Pyoderma gangrenosum) non est infectiosum. Curationes includunt corticosteroides, ciclosporinum, vel varia elementa monoclonalia. Etsi potest affectare homines cuiuslibet aetatis, maxime incidit in hominibus in decennio 40 et 50.
☆ AI Dermatology — Free Service
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
In crure hominis ulcerative colitis.
relevance score : -100.0%
ReferencesPyoderma gangrenosum rara cutis conditio est, quae ulcera dolorosa cum marginibus rubris vel purpureis producit. Morbus inflammatorius est et pars dermatosarum neutrophilicarum appellatur. Causae pyoderma gangrenosum multiplex sunt, quae difficultates cum immunitate innata et adaptiva implicat in hominibus qui genere proni sunt. Nuper, investigatores folliculum capillorum ut potentialem originem morbi proposuerunt.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum rara conditio cutis est, quae gravissima ulcerationes provocat. Quamquam eius causam nondum plene cognovimus, scimus quod actio eius a quibusdam cellulis immunibus augeri potest. De morbo adhuc difficile est. Habemus varia medicamenta quae systema immune reprimunt vel eius actionem modificant. Inter haec etiam vulnera curare et dolorem levare intendunt. Corticosteroides et cyclosporine saepe primum optio therapiae sunt, sed nuper plura studia in therapias biologicas, ut TNF-α inhibitores, facta sunt. Therapiae biologicae magis magisque praeferendae sunt, praesertim patientibus cum aliis conditionibus inflammatoriis, et in statu avans morbi adhibentur.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
